10 most-shorted biotech stocks of 2013

A lot of investors are betting these are going to fail. The No. 1 spot may surprise you.

By TheStreet Staff Jun 21, 2013 8:44AM

thestreet logoArrows and Lights © DAJ, amana images, Getty ImagesBy Adam Feuerstein


Here's a list of 10 bio-pharma stocks with the highest short interest as we near the mid-point of 2013, according to S&P Capital IQ. Many of the stocks on this list won't surprise anyone because they've been bull-bear battlegrounds for years. You might be surprised by the stock with the highest short interest today, so read on.


10. InterMune (ITMN)

Short interest: 22% of float.

Shorts say: The European commercial launch of Esbriet for the treatment of idiopathic pulmonary fibrosis -- a progressive lung disease -- is still a slow work in progress. Competition could negatively impact InterMune next year when Boehringer Ingelheim is expected to announce results from phase III studies of vargatef. Then there's the uncertainty surrounding InterMune's own U.S.-based phase III study of Esbriet -- results are also expected next year.ITMN graph

9. Hyperion Therapeutics (HPTX)

Short interest: 26% of float.

Shorts say: Can Hyperion really get away with charging $295,000 per year for Ravicti as a therapy for urea cycle disorders, even if it's more convenient than the less expensive alternative, Buphenyl?

Hyperion graph

8. Arena Pharmaceuticals (ARNA)

Short interest: 26.5% of float.

Shorts say: Belviq is a weak weight-loss drug. The commercial launch will be disappointing.

ARNA graph

7. Sunesis Pharmaceuticals (SNSS)

Short interest: 26.5% of float.

Shorts say: The phase III study of vosaroxin in acute myeloid leukemia will fail. [The decision to upsize the study last September was a negative tell.] Top-line results expected in the first half of 2014.

SNSS graph

6. Synta Pharmaceuticals (SNTA)

Short interest: 27% of float.

Shorts say: Synta designed the ongoing phase III lung cancer study of ganetespib around dubious, data-mined patient subgroup data. Like nearly all of these stories, the ending is tragic.

Synta graph

5. MannKind (MNKD)

Short interest: 29% of float.

Shorts say: Inhaled insulin? Really? Bwhahahaha!

MNKD graph

4. Ziopharm Oncology (ZIOP)

Short interest: 33% of float.

Shorts say: R.J. Kirk is full of $%^&.

ZIOP graph

3. Dendreon (DNDN)

Short interest: 35% of float.

Shorts say: Going out of business.

DNDN graph

2. Spectrum Pharmaceuticals (SPPI)

Short interest: 37% of float.

Shorts say: Is Raj still CEO? He is? Short!

Spectrum graph

And the most highly shorted biotech stock in 2013 is...


1. Sarepta Therapeutics (SRPT)

Short interest: 37.5% of float.

Shorts say: No eteplirsen accelerated approval.

(The drug is for the treatment of some mutations that cause Duchenne muscular dystrophy (DMD), a genetic degenerative muscle disease.)

Sarepta graph

More from TheStreet.com



Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.


StockScouter rates stocks from 1 to 10, with 10 being the best, using a system of advanced mathematics to determine a stock's expected risk and return. Ratings are displayed on a bell curve, meaning there will be fewer ratings of 1 and 10 and far more of 4 through 7.

123 rated 1
262 rated 2
480 rated 3
651 rated 4
649 rated 5
629 rated 6
616 rated 7
496 rated 8
346 rated 9
111 rated 10

Top Picks

TAT&T Inc9



Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.

Contributors include professional investors and journalists affiliated with MSN Money.

Follow us on Twitter @topstocksmsn.